Table 1.
Model Input | Source(s) | Serotype 1 Estimate | Serotype 2 Estimate | Serotype 3 Estimate |
---|---|---|---|---|
Basic reproduction number (R0) for WPV or fully reverted VDPV, relative to serotype 1 | [7, 37] | 1 (reference) | 0.9 | 0.75 |
Relative R0 of OPV parent strain to WPV or VDPV | [7] | 0.37 | 0.55 | 0.25 |
Average time (days) to revert from OPV to fully reverted VDPV | [37] | 620.5 | 408 | 620.5 |
Average paralysis-to-infection ratio for fully susceptible individuals | [7] | |||
WPV | 1/200 | 1/2000 | 1/1000 | |
OPV | 7.4 × 10–8 | 6.2 × 10–7 | 1.3 × 10–6 | |
Average per-dose OPV take rate for population modeled in Figure 2 | [21] | 0.42 (bOPV) | 0.60 (tOPV) | 0.42 (bOPV) |
Abbreviations: bOPV, bivalent oral poliovirus vaccine; OPV, oral poliovirus vaccine; tOPV, trivalent oral poliovirus vaccine; VDPV, vaccine-derived poliovirus; WPV, wild poliovirus.
aExcluding small serotype differences in characterization of immunity states [7].